Document:

Exhibit

Exhibit 10.2

AMENDMENT NO. 2 TO
CONTRIBUTION AGREEMENT
THIS AMENDMENT NO. 2 TO CONTRIBUTION AGREEMENT (this “Amendment”) is made as of August 10, 2017 by and between Celularity Inc., a Delaware corporation (the “Celularity”), and TNK Therapeutics, Inc., a Delaware corporation (“TNK”).
RECITALS
A.    Celularity, TNK and Sorrento Therapeutics, Inc., a Delaware corporation, have previously entered into that certain Contribution Agreement, dated June 12, 2017, as amended by that certain Amendment No. 1 to Contribution Agreement, dated June 30, 2017, by and between Celularity and TNK (collectively, the “Contribution Agreement”).
B.    Pursuant to Section 11.2 of the Contribution Agreement, the Contribution Agreement may be amended upon the written consent of Celularity and TNK.
C.    Celularity and TNK now desire to amend the Contribution Agreement to, among other things (1) set forth certain provisions regarding the intended treatment of the transactions described in the Contribution Agreement and certain other related transactions for Tax purposes, and (2) eliminate the requirement that the Parties be required to deliver counterparts of each of the Services Agreement, the Manufacturing Agreement and the Joint Program Agreement at the Closing, in each case as set forth herein. 
NOW THEREFORE, in consideration of the foregoing recitals and the mutual agreements contained herein, the parties hereto, intending to be legally bound, hereby agree as follows: 
1.Definitions; Construction.  Capitalized terms not otherwise defined herein shall have the meanings set forth in the Contribution Agreement.  References in the Contribution Agreement to “this Agreement” (and indirect references such as “hereunder”, “hereby”, “herein” and “hereof”) shall be deemed to be references to the Contribution Agreement, as amended hereby.
2.Definitions Table.  The line item “Accounting Firm” in the table under the heading “Additional Defined Terms” in Section 1.1 of the Contribution Agreement shall be amended and restated in its entirety as follows:
“Intended Tax Treatment                2.2”
3.Tax Provisions.  Section 2.2 of the Contribution Agreement is hereby amended and restated in its entirety as follows: 
“Section 2.2    Intended Tax Treatment.  The Parties intend that the contribution of property to Celularity in exchange for the Celularity Shares pursuant to the Contribution described in the Contribution Agreement, in connection with certain other related transactions, shall be treated for U.S. federal and applicable state and local tax purposes as a transfer of property in exchange for stock in a corporation under Section 351 of the Code (the “Intended Tax Treatment”).  Except as otherwise required by applicable law, the Parties agree to prepare and file all Tax Returns in a manner consistent with the Intended Tax Treatment (including filing the statements required by Treasury Regulation Section 1.351-3 with its federal income Tax Return filed for the taxable year which includes the Closing Date), and to not take any contrary position on any Tax Return and to notify the other Parties of any communication from the IRS or any other taxing authority of any challenge to the Intended Tax Treatment.  At least thirty (30) days prior to the due date thereof, Celularity shall provide Sorrento a copy of its federal income Tax Return and any applicable state income Tax Return for the taxable year which includes the Closing Date.  Sorrento shall have fifteen (15) days to review each such Tax Return and provide comments thereto (solely with respect to the Intended Tax Treatment).  Celularity shall reflect on each such Tax Return any reasonable comments proposed thereto by Sorrento in regards to the reflection of the Intended Tax Treatment.  Each of the Parties further agrees to cooperate in good faith with the other Party in all future Tax Returns or other filings or communications with the IRS or any other taxing authority with respect to all Tax matters pertinent to the Intended Tax Treatment.”
4.Celularity Closing Deliveries.  Section 3.3(a) of the Contribution Agreement is hereby amended and restated in its entirety as follows: 
“(a)    duly executed counterparts of each of the Transaction Documents (other than the Services Agreement, the Manufacturing Agreement and the Joint Program Agreement) to which Celularity or its Affiliates is a party;”
5.TNK Closing Deliveries.  Section 3.4(a) of the Contribution Agreement is hereby amended and restated in its entirety as follows: 
“(a)    duly executed counterparts of each of the Transaction Documents (other than the Services Agreement, the Manufacturing Agreement and the Joint Program Agreement) to which TNK, Sorrento, or their respective Affiliates is a party;”
6.Effect of Termination.  The first sentence of Section 9.2 of the Contribution Agreement is hereby amended and restated in its entirety as follows: 
“Termination of this Agreement pursuant to this Article IX shall terminate all obligations of the Parties, except for the obligations under this Section 9.2 or Section 2.2, Section 11.1, Section 11.5 or Section 11.6 hereof, provided, that nothing in this Section 9.2 shall relieve or limit the liability hereunder of any Party (the “Defaulting Party”) to another Party on account of fraud or in connection with a willful and material breach of this Agreement by the Defaulting Party.”
7.Miscellaneous.  Except as specifically set forth herein, all of the terms and provisions of the Contribution Agreement shall remain unchanged, unmodified and in full force and effect, and the Contribution Agreement shall be read together with and construed with this Amendment.  This Amendment may be executed in any number of counterparts, all of which when taken together shall constitute one and the same amendatory instrument and any of the parties hereto may executed this Amendment by signing one counterpart.  Any signature page delivered by facsimile or e-mail transmission of images in Adobe PDF or similar format shall be binding to the same extent as an original signature page.
[Signature Page Follows]

IN WITNESS WHEREOF, the parties have executed this Amendment No. 2 to Contribution Agreement as of the date first written above. 

	
			
	CELULARITY:

	 
	TNK:

	Celularity, Inc.

By: /s/ Robert Hariri             
Name: Robert Hariri 
Its: Chief Executive Officer
	 
	TNK Therapeutics, Inc.

By:/s/ Henry Ji, Ph.D.             
Name: Henry Ji, Ph.D.  
Its: Chief Executive OfficerExhibit

Exhibit 10.3
*** Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4)
and 240.24b-2

SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT
THIS SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of November 6, 2017 (the “Seventh Amendment Effective Date”), is entered into by and among Sorrento Therapeutics, Inc., a Delaware corporation (“Parent”), Concortis Biosystems, Corp., a Delaware corporation, Ark Animal Health, Inc., a Delaware corporation, TNK Therapeutics, Inc., a Delaware corporation, Sorrento Biologics, Inc., a Delaware corporation, Scintilla Pharmaceuticals, Inc., a Delaware corporation, LA Cell, Inc., a Delaware corporation, SiniWest Holding Corp., a Delaware corporation, Levena Biopharma US, Inc., a Delaware corporation, BioServ Corporation (formerly known as Sorrento BioServices, Inc.), a Delaware corporation, Scilex Pharmaceuticals Inc., a Delaware corporation, SNAN Holdco LLC, a Delaware limited liability company and each of their Qualified Subsidiaries (together with “Parent” hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time parties thereto as Lender, constituting the Required Lenders, and HERCULES CAPITAL, INC., formerly known as Hercules Technology Growth Capital, Inc., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lender (in such capacity, together with its successors and assigns in such capacity, “Agent”).
The Borrower, the Lender and Agent are parties to a Loan and Security Agreement dated as of November 23, 2016 (as amended by that certain First Amendment to Loan and Security Agreement dated as of December 27, 2016, that certain Second Amendment to Loan and Security Agreement dated as of March 2, 2017, that certain Third Amendment to Loan and Security Agreement dated as of March 15, 2017, that certain Fourth Amendment to Loan and Security Agreement dated as of March 23, 2017, that certain Fifth Amendment to Loan and Security Agreement dated as of April 13, 2017, that certain Sixth Amendment to Loan and Security Agreement dated as of April 27, 2017, and as may be further amended, restated or modified from time to time, the “Loan and Security Agreement”).  The Borrower has requested that the Lender agree to certain amendments to the Loan and Security Agreement.  The Lender has agreed to such request, subject to the terms and conditions hereof.
Accordingly, the parties hereto agree as follows:
SECTION 1Definitions; Interpretation.
(a)    Terms Defined in Loan and Security Agreement.  All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan and Security Agreement.
(b)    Interpretation.  The rules of interpretation set forth in Section 1.1 of the Loan and Security Agreement shall be applicable to this Amendment and are incorporated herein by this reference.
SECTION 2    Amendments to the Loan and Security Agreement.  The Loan and Security Agreement shall be amended as follows effective as of the Seventh Amendment Effective Date:

(a)    Deletions of Definitions.  The Loan and Security Agreement shall be amended by deleting the following definitions from Section 1.1 of the Loan and Security Agreement in their entirety: “Corporate Milestone”, “Fundraising Milestone” and “Milestones”.

1

(b)    Amended Definition.  The following definition in Section 1.1 of the Loan and Security Agreement is hereby amended as follows:
[...***...]
(c)    Section 7.21.  Section 7.21 of the Loan and Security Agreement is hereby amended and restated in its entirety as follows:
7.21 Minimum Cash. Borrower shall maintain Unrestricted Cash in an amount greater than or equal to Eight Million Dollars ($8,000,000) plus the amount of Borrower’s accounts payable under GAAP not paid after the 90th day following the invoice date for such accounts payable. Borrower shall provide Agent evidence of compliance with the financial covenants under this Section 7.21 (a) no less frequently than weekly, (b) in each Compliance Certificate and (c) upon request, in each case in form and substance acceptable to Agent and with supporting documentation requested by Agent, including, without limitation, evidence of bank statement activity from such week (including ending balances) and certification of such compliance by the Chief Executive Officer or Chief Financial Officer of Borrower.

(d)    Compliance Certificate.  Exhibit F (Compliance Certificate) of the Loan and Security Agreement is hereby amended and restated in its entirety as set forth in Addendum I hereto.
(e)    References Within Loan and Security Agreement.  Each reference in the Loan and Security Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment.
SECTION 3    Consent.
(a)    Subject to the terms of this Amendment, Agent and the Lenders hereby consent to the repayment on the date hereof of Ten Million Dollars ($10,000,000) in outstanding principal and unpaid interest thereon (exclusive of the Fourth Amendment Repayment) (the “Seventh Amendment Repayment”).  Agent and Lenders hereby agree that such Seventh Amendment Repayment shall not be subject to the Prepayment Charge.
(b)    The consent set forth in this Section 3 is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (i) be a consent to any 

amendment, waiver or modification of any other term or condition of any Loan Document (including any other payments of the Prepayment Charge), or (ii) otherwise prejudice any right or remedy which Agent or the Lenders may now have or may have in the future under or in connection with any Loan Document.
SECTION 4    Conditions of Effectiveness.  The effectiveness of Sections 2 and 3 of this Amendment shall be subject to the satisfaction of each of the following conditions precedent:
(a)    Prepayment.  The Borrower shall have paid the Seventh Amendment Repayment.  

* Confidential Treatment Requested
2

(b)    Fees and Expenses.  The Borrower shall have paid (i) all attorney fees and other costs and expenses then due in accordance with Section 6(e), and (ii) all other fees, costs and expenses, if any, due and payable as of the Seventh Amendment Effective Date under the Loan and Security Agreement.
(c)    This Amendment.  Agent shall have received this Amendment, executed by Agent, the Lender and the Borrower.
(d)    Representations and Warranties; No Default.  On the Seventh Amendment Effective Date, after giving effect to the amendment of the Loan and Security Agreement contemplated hereby:
(i)    The representations and warranties contained in Section 5 shall be true and correct in all material respects on and as of the Seventh Amendment Effective Date as though made on and as of such date; and
(ii)    There exist no Events of Default or events that with the passage of time would result in an Event of Default.
SECTION 5    Representations and Warranties.  To induce Agent and Lender to enter into this Amendment, the Borrower hereby confirms, as of the date hereof, (a) that the representations and warranties made by it in Section 5 of the Loan and Security Agreement and in the other Loan Documents are true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; (b) that there has not been and there does not exist a Material Adverse Effect; and (c) that the information included in the Perfection Certificate delivered to Agent on the Effective Date remains true and correct.  For the purposes of this Section 5, any representations and warranties which relate solely to an earlier date shall not be deemed confirmed and restated as of the date hereof (provided that such representations and warranties shall be true, correct and complete in all material respects as of such earlier date).
SECTION 6    Miscellaneous.
(a)    Loan Documents Otherwise Not Affected; Reaffirmation.  Except as expressly amended pursuant hereto or referenced herein, the Loan and Security Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects.  The Lender’s and Agent’s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future.  The Borrower hereby reaffirms the grant of security under Section 3.1 of the Loan and Security Agreement and hereby reaffirms that such grant of security in the Collateral secures all Secured Obligations under the Loan and Security Agreement, including without limitation any Term Loans funded on or after the Seventh Amendment Effective Date, as of the date hereof.
(b)    Conditions.  For purposes of determining compliance with the conditions specified in Section 4, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented 

3

to or approved by or acceptable or satisfactory to a Lender unless Agent shall have received notice from such Lender prior to the Seventh Amendment Effective Date specifying its objection thereto.
(c)    Release.  In consideration of the agreements of Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account of, or in relation to, or in any way in connection with the Loan and Security Agreement, or any of the other Loan Documents or transactions thereunder or related thereto.  Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.  Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.
(d)    No Reliance.  The Borrower hereby acknowledges and confirms to Agent and the Lender that the Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.
(e)    Costs and Expenses.  The Borrower agrees to pay to Agent on the Seventh Amendment Effective Date the out-of-pocket costs and expenses of Agent and the Lenders party hereto, and the fees and disbursements of counsel to Agent and the Lenders party hereto (including allocated costs of internal counsel), in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the Seventh Amendment Effective Date or after such date.
(f)    Binding Effect.  This Amendment binds and is for the benefit of the successors and permitted assigns of each party.  
(g)    Governing Law.  This Amendment, the Loan and Security Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

4

(h)    Complete Agreement; Amendments.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.  
(i)    Severability of Provisions.  Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.
(j)    Counterparts.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment.  Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.
(k)    Loan Documents. This Amendment shall constitute a Loan Document.
[Balance of Page Intentionally Left Blank; Signature Pages Follow] 

IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.
BORROWER:

SORRENTO THERAPEUTICS, INC.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

CONCORTIS BIOSYSTEMS, CORP.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

ARK ANIMAL HEALTH, INC.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

SORRENTO BIOLOGICS, INC.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

TNK THERAPEUTICS, INC.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

SCINTILLA PHARMACEUTICALS, INC.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

LA CELL, INC.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

SINIWEST HOLDING CORP.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

LEVENA BIOPHARMA US INC.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

BIOSERV CORPORATION 
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

SCILEX PHARMACEUTICALS INC.
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

SNAN HOLDCO LLC
Signature:    /s/ Henry Ji            
Print Name:    Henry Ji
Title:        CEO

AGENT:
HERCULES CAPITAL, INC.
Signature:    /s/ Jennifer Choe        
Print Name:    Jennifer Choe
Title:        Assistant General Counsel

LENDER:
HERCULES CAPITAL, INC.
Signature:    /s/ Jennifer Choe        
Print Name:    Jennifer Choe
Title:        Assistant General Counsel

    

ADDENDUM I
EXHIBIT F
COMPLIANCE CERTIFICATE
Hercules Capital, Inc. (as “Agent”) 
400 Hamilton Avenue, Suite 310 
Palo Alto, CA 94301
Reference is made to that certain Loan and Security Agreement dated November 23, 2016 and the Loan Documents (as defined therein) entered into in connection with such Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as the “Loan Agreement”) by and among Hercules Capital, Inc. (the “Agent”), the several banks and other financial institutions or entities from time to time party thereto (collectively, the “Lender”) and Hercules Capital, Inc., as agent for the Lender (the “Agent”) and Sorrento Therapeutics, Inc. (the “Company”) and each other Qualified Subsidiary as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.
The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification of information regarding the Company; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period ending ___________ of all covenants, conditions and terms of the Loan Agreement and hereby reaffirms that all representations and warranties contained therein are true and correct in all material respects on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties.  Attached are the required documents supporting the above certification.  The undersigned further certifies that these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statements and subject to normal year-end adjustments) and are consistent from one period to the next except as explained below.
	
			
	REPORTING REQUIREMENT
	REQUIRED
	CHECK IF ATTACHED

	Interim Balance Sheet and/or Financial Statements (as required pursuant to Section 7.1(a))
	Monthly within 45 days
	 

	Interim Financial Statements
	Quarterly within 45 days
	 

	Audited Financial Statements
	FYE within 90 days
	 

7.21 – Minimum Cash
(A) Unrestricted Cash: $___________
(B) amount of Borrower’s accounts payable under GAAP and not paid after the 90th day following the invoice date for such accounts payable: $___________
(C) item (A) minus item (B): $___________
Is item (C) greater than or equal to $8,000,000?
__ Yes (in compliance); __ No (not in compliance)

The undersigned hereby also confirms the below disclosed accounts represent all depository accounts and securities accounts presently open in the name of each Borrower or Borrower Subsidiary/Affiliate, as applicable.
	
							
	 
	 
	Depository AC #
	Financial Institution
	Account Type (Depository / Securities)
	Last Month Ending Account Balance
	Purpose of Account

	BORROWER Name/Address:
	 

	 
	1
	 
	 
	 
	 
	 

	2
	 
	 
	 
	 
	 

	3
	 
	 
	 
	 
	 

	4
	 
	 
	 
	 
	 

	5
	 
	 
	 
	 
	 

	6
	 
	 
	 
	 
	 

	7
	 
	 
	 
	 
	 

	 

	BORROWER SUBSIDIARY / AFFILIATE COMPANY Name/Address
	 

	 
	1
	 
	 
	 
	 
	 

	2
	 
	 
	 
	 
	 

	3
	 
	 
	 
	 
	 

	4
	 
	 
	 
	 
	 

	5
	 
	 
	 
	 
	 

	6
	 
	 
	 
	 
	 

	7
	 
	 
	 
	 
	 

	 

Very Truly Yours,
Sorrento Therapeutics, Inc.
		
	By:
	____________________________

Name:   _____________________________
		
	Its:
	____________________________

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]